查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年神经免疫药物市场预测：按产品类型、适应症和地区分類的全球分析
市场调查报告书
商品编码
1383453

2030 年神经免疫药物市场预测：按产品类型、适应症和地区分類的全球分析

Neuroimmunology Drugs Market Forecasts to 2030 - Global Analysis By Product Type (Monoclonal Antibodies, Small Molecules, Recombinant Protein, Cytokines, Lymphocytes and Other Product Types), Indication and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球神经免疫药物市场规模为 238.7 亿美元，预计在预测期内将以 9.5% 的年复合成长率增长，到 2030 年达到 450.5 亿美元。

神经免疫药物市场专注于治疗涉及神经和免疫系统的疾病。这包括影响神经系统的疾病，例如视神经脊髓炎 (NMO)、多发性硬化症 (MS) 和其他自体免疫疾病。该领域的许多神经系统疾病都属于自体自体免疫疾病的范畴，其中免疫系统会错误识别并攻击神经系统成分，例如多发性硬化症（MS）中的髓鞘。

神经免疫疾病的发生率增加

随着越来越多的人被诊断出患有神经免疫疾病，需要治疗的患者数量也会增加，增加了对神经免疫治疗的需求。随着这些病理数量的增加，寻找更有效治疗方法的研究和开发配合措施也不断增加。製药公司正在投入资源开发新药，以满足不断增加的患者需求。新药的开发是为了满足更多患者群体和改善治疗结果的需求。科学家和製药公司正在研究新策略和前沿药物治疗前景。

开发成本高

研发投资可能会受到高昂的开发成本的限制，这使得新兴企业在财务上难以推出和维持开发神经免疫疾病疗法的计划。我不知道。为了收回开发成本并产生利润，神经免疫药物公司可能会收取溢价。因此，过高的药品价格会限制患者的取得和负担能力，并降低治疗效果。

创新药物研发

随着科学进步，新的药物标靶、途径和可能的治疗方法不断被发现。这将鼓励开发神经免疫疾病的新药和治疗方法。改进研究可以促进学术机构、研究小组和製药公司之间的合作。此外，这些小组的努力加速了知识交流和研究与开发，确定了与神经免疫疾病相关的特定细胞和分子靶标，并推进了研究。因此，针对各种疾病的根本原因并改变免疫反应的特异性治疗方法正在开发中。

激烈的竞争

当公司降低药品价格以获取或维持市场占有率时，过度的市场竞争会对定价造成压力。这可能会影响药物研究的盈利，儘管它可以透过节省资金来帮助患者。药物的研究和核准过程可能会仓促，以帮助製药公司保持竞争力，引发对其有效性和安全性的质疑。这不仅会危及病人安全，还会危及产业信任。为了减少市场竞争的负面影响，重要的是要专注于治疗进展，同时保持法规监督、品质基准和严格的研发标准。

COVID-19 的影响

封锁和其他限制延迟或阻止了一些研究活动，包括临床试验和实验室研究。这推迟了正在进行的神经免疫药物倡议的开发。一些製药公司可能已将重点从神经免疫学药物开发转移，转而将研究工作和资源集中在与 COVID-19 相关的治疗和疫苗上。因此，可能会出现药品短缺或生产延误，这对市场成长产生负面影响。

单株抗体领域预计将成为预测期内最大的市场

由于单株抗体经常被用作包括多发性硬化症 (MS) 和视神经脊髓炎 (NMO) 在内的神经免疫疾病的疾病缓解疾病疗法，因此单株抗体领域预计将经历良好的增长。为了减少发炎和抑制发炎反应，这些单株抗体可能能够减缓疾病进程并避免復发。发炎是许多神经免疫疾病的主要因素，单株抗体可以减轻发炎、缓解不适并阻止神经组织损伤。某些单株抗体的作用是防止自体自体免疫系统攻击髓鞘等神经系统成分，有助于防止神经系统受到伤害。

多发性硬化症领域预计在预测期内具有最高的年复合成长率

预计多发性硬化症领域在预测期内将呈现最高的年复合成长率。这是因为多发性硬化症（MS）是神经免疫疗法市场上最常见的神经系统疾病之一。在多发性硬化症（MS）这种自体免疫疾病中，免疫系统错误地攻击中枢神经系统（CNS）神经纤维周围的保护性髓磷脂层。这种疾病会引起许多神经系统症状。此外，由于正在进行的研究，正在开发新的治疗方法，并且正在重新调整现有药物来治疗多发性硬化症。因此，这些最先进治疗的目标是更好的结果和更多的治疗选择。

占比最大的地区：

由于多发性硬化症、视神经脊髓炎和其他自体自体免疫神经系统疾病等神经免疫疾病在该地区变得越来越普遍，预计亚太地区将在预测期内占据最大的市场占有率。由于治疗方案的改进、早期诊断以及对神经免疫疾病的认知提高，确切的盛行率因国家和地区而异。许多地方政府正在改善神经免疫疾病的管理。这包括资助研究、扩大医疗保健基础设施以及鼓励早期发现和早期疗育。

复合年复合成长率最高的地区：

预计北美在预测期内的年复合成长率最高。这是因为许多神经免疫学相关药物的临床试验都是在北美进行的。北美因其强大的医疗保健系统、研究机构和多样化的患者基础而成为进行临床研究的理想地点。美国食品药物管理局（FDA）和加拿大卫生署是两个法规机构，负责确保神经免疫学相关药物的安全性和有效性，并为药物核准建立既定的法规结构。在北美，许多患者都有健康保险，这可以减少自付费用并改善获得神经免疫治疗的机会。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球神经免疫药物市场：依产品类型

  • 单株抗体
  • 低分子
  • 重组蛋白
  • 细胞因子
  • 淋巴球
  • 其他产品类型

第6章全球神经免疫药物市场：依适应症分类

  • 多发性硬化症
  • 阿兹海默症
  • 帕金森氏症
  • 重症肌无力
  • 格林-巴利症候群
  • 视神经脊髓炎谱系障碍
  • 肌萎缩侧索硬化症
  • 慢性发炎去髓鞘化神经病变
  • 其他适应症

第7章全球神经免疫药物市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第8章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第9章公司简介

  • Biogen
  • Hoffmann-La Roche Ltd
  • T3D Therapeutics
  • Novartis AG
  • Celgene Corp
  • Merck KGaA
  • Johnson & Johnson
  • Eisai Co Ltd
  • Sanofi
  • Actelion Pharmaceuticals Ltd.
  • ImmunoBrain Checkpoint
  • Lundbeck
  • Eli Lilly
  • AstraZeneca
  • UCB SA
  • AB Science SA
  • AstronauTx
  • Genetech Inc
  • Inflammasome Therapeutics
  • TauRX Therapeutics Ltd
Product Code: SMRC24301

According to Stratistics MRC, the Global Neuroimmunology Drugs Market is accounted for $23.87 billion in 2023 and is expected to reach $45.05 billion by 2030 growing at a CAGR of 9.5% during the forecast period. The market for neuroimmunology drugs is mostly focused on the treatment of illnesses involving the neurological and immune systems. This covers conditions that affect the neurological system, such as neuromyelitis optica (NMO), multiple sclerosis (MS), and other autoimmune illnesses. Many of the neurological disorders in this area fall within the category of autoimmune illnesses, in which the immune system misidentifies and attacks nervous system components, including the myelin sheath in multiple sclerosis (MS).

Market Dynamics:

Driver:

Increasing incidence of neuroimmunological disorders

As more people receive diagnoses for neuroimmunological illnesses, there will be a greater number of patients in need of care thus the need for neuroimmunology medications is fueled by this. Increased efforts are being made in research and development to identify more effective therapies as a result of the rising occurrence of these conditions. Pharmaceutical corporations allocate resources towards the creation of novel medications to cater to the growing number of patients. The creation of novel medicines is aided by the requirement to serve a wider patient population and to enhance treatment outcomes; scientists and pharmaceutical companies investigate fresh strategies and cutting-edge medication prospects.

Restraint:

High development costs

Research & development investment may be discouraged by high development costs and it may be financially difficult for startups and smaller pharmaceutical companies to launch or maintain medication development projects for neuroimmunological illnesses. In order to recover development expenses and generate a profit, neuroimmunology pharmaceutical companies could set their prices at premium levels. Thus, the excessive medicine costs may make treatment less effective by limiting patient access and affordability.

Opportunity:

Innovative drug developments

New drug targets, routes, and possible treatments are found as a result of scientific advances. This motivates the creation of novel medications and therapeutic modalities for neuroimmunological illnesses. Research improvements enable collaboration among academic institutions, research groups, and pharmaceutical businesses. Moreover, the knowledge exchange and medication development are accelerated by this group effort and research progresses in identifying certain cellular and molecular targets linked to neuroimmunological diseases. As a result, specific treatments that target the underlying causes of various illnesses and modify the immune response are developed.

Threat:

Intense rivalry

Competition that is too fierce might put pressure on pricing because businesses would drop the price of their drugs to get or keep market share. This may have an effect on the profitability of medication research, even while it can help patients by saving money. Drug research and approval processes may be hurried by pharmaceutical corporations in an effort to stay competitive, raising questions about their efficacy and safety. Patient safety as well as industry confidence may be jeopardized by this. To mitigate the possible adverse consequences of market competition, regulatory supervision, quality benchmarks, and a dedication to therapeutic advancement while upholding rigorous R&D standards are crucial.

COVID-19 Impact

Lockdowns and other limitations caused several research activities including clinical trials and laboratory research to be postponed or hindered. This slowed down the development of on-going neuroimmunology medication initiatives. Some pharmaceutical firms may have changed their focus away from developing drugs for neuroimmunology and instead concentrated their research efforts and resources toward COVID-19-related therapies and vaccines. This resulted in possible shortages and production delays of pharmaceuticals thus negatively impacted the market growth.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is estimated to have a lucrative growth, as these disease modifying treatments for neuroimmunological conditions including multiple sclerosis (MS) and neuromyelitis optica (NMO), monoclonal antibodies are frequently used. With the goal of lowering inflammation and suppressing the inflammatory response, these mAbs may be able to delay the course of the illness and avoid relapses. A major factor in many neuroimmunological illnesses is inflammation and inflammation can be lessened by monoclonal antibodies, which can aid with discomfort relief and stop more nerve tissue damage. Certain mAbs function by preventing the autoimmune system from attacking nervous system elements like the myelin sheath thus they aid in preventing harm to the neurological system by doing this.

The multiple sclerosis segment is expected to have the highest CAGR during the forecast period

The multiple sclerosis segment is anticipated to witness the highest CAGR growth during the forecast period, as it is one of the most common neurological disorders in the market for neuroimmunology medications is multiple sclerosis (MS). The protective myelin layer that envelops nerve fibres in the central nervous system (CNS) is wrongly attacked by the immune system in multiple sclerosis (MS), an autoimmune illness. Numerous neurological symptoms are caused by this illness. Moreover novel treatments are being developed and current medications are being repurposed for the treatment of multiple sclerosis as a result of on-going research thus the goals of these cutting-edge treatments are better results and more treatment alternatives.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to neuroimmunological diseases like multiple sclerosis, neuromyelitis optica, and other autoimmune nervous system illnesses have become more common in the Asia-Pacific area. Each nation and area has a different precise prevalence as a result of improved treatment options, early diagnosis, and growing awareness of neuroimmunological illnesses. The management of neuroimmunological illnesses is being improved by a number of regional governments. This entails providing money for research, expanding the infrastructure for healthcare, and encouraging early detection and intervention.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period; owing to the clinical trials for medications linked to neuroimmunology which are mostly conducted in North America. It's a desirable place to do clinical research because of its strong healthcare system, research institutes, and varied patient base. The U.S. Food and Drug Administration (FDA) and Health Canada are two regulatory bodies that guarantee the safety and effectiveness of neuroimmunology medications, creating a well-established regulatory framework for drug approval. In North America, a large number of patients have health insurance, which can help to lower out-of-pocket treatment expenses and improve access to neuroimmunology medications.

Key players in the market

Some of the key players profiled in the Neuroimmunology Drugs Market include: Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, Novartis AG, Celgene Corp, Merck KGaA, Johnson & Johnson, Eisai Co Ltd, Sanofi, Actelion Pharmaceuticals Ltd., ImmunoBrain Checkpoint, Lundbeck, Eli Lilly, AstraZeneca, UCB SA, AB Science S.A., AstronauTx, Genetech Inc, Inflammasome Therapeutics and TauRX Therapeutics Ltd

Key Developments:

In September 2023, Biogen Inc has completed the acquisition of Reata Pharmaceuticals, Inc. a company focused on developing therapeutics that regulates cellular metabolism and inflammation in serious neurologic diseases.

In June 2023, Roche announced that they had entered into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant's RVT-3101.

In April 2023, T3D Therapeutics, Inc. a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator

Product Types Covered:

  • Monoclonal Antibodies
  • Small Molecules
  • Recombinant Protein
  • Cytokines
  • Lymphocytes
  • Other Product Types

Indications Covered:

  • Multiple Sclerosis
  • Alzheimer's Disease
  • Parkinson's Disease
  • Myasthenia Gravis
  • Guillain-Barre Syndrome
  • Neuromyelitis Optica Spectrum Disorder
  • Amyotrophic Lateral Sclerosis
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Other Indications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuroimmunology Drugs Market, By Product Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Small Molecules
  • 5.4 Recombinant Protein
  • 5.5 Cytokines
  • 5.6 Lymphocytes
  • 5.7 Other Product Types

6 Global Neuroimmunology Drugs Market, By Indication

  • 6.1 Introduction
  • 6.2 Multiple Sclerosis
  • 6.3 Alzheimer's Disease
  • 6.4 Parkinson's Disease
  • 6.5 Myasthenia Gravis
  • 6.6 Guillain-Barre Syndrome
  • 6.7 Neuromyelitis Optica Spectrum Disorder
  • 6.8 Amyotrophic Lateral Sclerosis
  • 6.9 Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • 6.10 Other Indications

7 Global Neuroimmunology Drugs Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Biogen
  • 9.2 Hoffmann-La Roche Ltd
  • 9.3 T3D Therapeutics
  • 9.4 Novartis AG
  • 9.5 Celgene Corp
  • 9.6 Merck KGaA
  • 9.7 Johnson & Johnson
  • 9.8 Eisai Co Ltd
  • 9.9 Sanofi
  • 9.10 Actelion Pharmaceuticals Ltd.
  • 9.11 ImmunoBrain Checkpoint
  • 9.12 Lundbeck
  • 9.13 Eli Lilly
  • 9.14 AstraZeneca
  • 9.15 UCB SA
  • 9.16 AB Science S.A.
  • 9.17 AstronauTx
  • 9.18 Genetech Inc
  • 9.19 Inflammasome Therapeutics
  • 9.20 TauRX Therapeutics Ltd

List of Tables

  • Table 1 Global Neuroimmunology Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 5 Global Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 6 Global Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 7 Global Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 8 Global Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 9 Global Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 10 Global Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 11 Global Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 12 Global Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 13 Global Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 14 Global Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 15 Global Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 16 Global Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 17 Global Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 18 Global Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 19 North America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 20 North America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 21 North America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 22 North America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 23 North America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 24 North America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 25 North America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 26 North America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 27 North America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 28 North America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 29 North America Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 30 North America Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 31 North America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 32 North America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 33 North America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 34 North America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 35 North America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 36 North America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 37 Europe Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Europe Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 39 Europe Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 40 Europe Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 41 Europe Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 42 Europe Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 43 Europe Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 44 Europe Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 45 Europe Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 46 Europe Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 47 Europe Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 48 Europe Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 49 Europe Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 50 Europe Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 51 Europe Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 52 Europe Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 53 Europe Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 54 Europe Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 55 Asia Pacific Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 56 Asia Pacific Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 57 Asia Pacific Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 58 Asia Pacific Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 59 Asia Pacific Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 60 Asia Pacific Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 61 Asia Pacific Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 62 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 63 Asia Pacific Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 64 Asia Pacific Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 65 Asia Pacific Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 66 Asia Pacific Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 67 Asia Pacific Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 68 Asia Pacific Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 69 Asia Pacific Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 70 Asia Pacific Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 71 Asia Pacific Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 72 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 73 South America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 South America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 75 South America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 76 South America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 77 South America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 78 South America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 79 South America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 80 South America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 81 South America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 82 South America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 83 South America Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 84 South America Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 85 South America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 86 South America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 87 South America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 88 South America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 89 South America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 90 South America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 91 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 92 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 93 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 94 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 95 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 96 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 97 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 98 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 99 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 100 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 101 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 102 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 103 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 104 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 105 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 106 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 107 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 108 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)